Anavex Life Sciences Corp (AVXL)

[falconer66a]

Again, blarcamesine-induced prevention of Alzheimer’s.

On average, blarcamesine 30 mg/day stabilizes Alzheimer's disease;

If that’s the case, it would then stand to reason that if 30mg of blarcamesine were administered to people detected to be vulnerable to Alzheimer’s, but don’t yet have any overt or frank symptoms, that no-symptoms condition would be “stabilized,” kept or maintained at that pre- or non-symptomatic stage. Prophylaxis; prevention of the onset of symptoms. Blarcamesine-induced stabilization of the pre-disease state in those determined to otherwise be vulnerable or destined to suffer from Alzheimer’s.

With the multitude of new, accurate tests for Alzheimer’s vulnerabilities, it will be possible for people, in annual health checkups with their general practice physicians to be tested and if indicated begin blarcamesine therapy before Alzheimer’s symptoms even begin. The disease will be prevented from its natural onset and lethal progression. Stop it before it begins. Stabilize things in the pre-disease stage.